Valuation : Perspective Therapeutics, Inc.

Market Cap 355M 306M 287M 262M 493M 33.93B 495M 3.4B 1.33B 17.13B 1.33B 1.3B 56.79B P/E 2026 *
-3.11x
P/E 2027 * -2.93x
Enterprise Value 188M 162M 152M 139M 262M 18.01B 263M 1.81B 705M 9.09B 708M 692M 30.15B EV / Sales 2026 *
578x
EV / Sales 2027 * 339x
Free-Float
89.2%
Yield 2026 *
-
Yield 2027 * -
1 day-2.20%
1 week-5.76%
Current month+6.87%
1 month+8.36%
3 months-23.21%
6 months-42.41%
Current year+13.09%
1 week 3.08
Extreme 3.075
3.37
1 month 2.83
Extreme 2.83
3.56
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2023
Director of Finance/CFO 59 04/09/2025
Chief Tech/Sci/R&D Officer - 08/07/2026
Director TitleAgeSince
Director/Board Member 54 05/02/2023
Chairman 63 03/02/2023
Director/Board Member 60 05/02/2023
Date Insider Type Main position Quantity % Market Cap.
2/3/26 Free

Director

50,000 0.0439%
2/3/26 Free

Director

50,000 0.0439%
2/3/26 Free

Controller/Auditor

90,000 0.0790%
Change 5-day change 1-year change 3-year change Capi.($)
-2.20%-5.76%-7.99%-21.07% 355M
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+442.41%+544.39% 44.56B
-0.24%+0.74%+38.69%+18.02% 43.08B
-1.55%-2.07%+23.08%+81.47% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+27.00%+129.56% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.60%+27.75% 14.58B
-1.66%-1.25%+78.59%+46.66% 13.92B
Average -1.60%-1.53%+70.23%+100.11% 27.49B
Weighted average by Cap. -1.70%-1.07%+95.57%+133.42%

Financials

2026 *2027 *
Net sales 326K 281K 263K 240K 453K 31.14M 454K 3.12M 1.22M 15.72M 1.22M 1.2M 52.12M 366K 315K 295K 270K 508K 34.95M 510K 3.51M 1.37M 17.64M 1.37M 1.34M 58.5M
Net income -115M -99.5M -93.29M -85.16M -160M -11.04B -161M -1.11B -432M -5.57B -434M -424M -18.47B -136M -117M -110M -100M -189M -13.02B -190M -1.31B -509M -6.57B -511M -500M -21.79B
Net Debt -167M -144M -135M -123M -231M -15.92B -232M -1.6B -623M -8.04B -625M -612M -26.64B -231M -199M -187M -170M -321M -22.06B -322M -2.21B -863M -11.14B -867M -848M -36.93B
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
28/08/26 US$3.110 -2.20% 913,334
27/08/26 US$3.180 +0.63% 797,531
26/08/26 US$3.160 -3.95% 799,217
25/08/26 US$3.290 +3.13% 773,771
24/08/26 US$3.190 -3.33% 678,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3.110USD
Average target price
12.53USD
Spread / Average Target
+303.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock